Replimune Group, Inc.

What they do

Replimune develops oncolytic immunotherapies based on its proprietary RPx platform, an engineered herpes simplex virus type 1 (HSV-1) backbone designed to kill tumors directly and activate a systemic anti-tumor immune response. The company's lead product candidate, RP1 (now TUDRIQEV), is approved in combination with nivolumab for advanced melanoma, and it is also developing RP2 and RP3. Replimune conducts clinical trials in collaboration with Bristol Myers Squibb, which supplies nivolumab at no cost.

Revenue drivers

• TUDRIQEV (RP1) in combination with nivolumab — Approved by the FDA on August 6, 2026, for unresectable advanced cutaneous melanoma after progression on a PD-1 antibody-based regimen. This is the company's first commercial product and primary source of future revenue, with launch expected within 60 days.
• RP2 (sturlimgene erparepvec) — Currently in a registration-directed Phase 2/3 trial (REVEAL) for metastatic uveal melanoma. Not yet approved; no current revenue.
• RP3 — Third product candidate in the RPx platform pipeline. Early-stage; no revenue expected in the near term.

Recent performance

For the fiscal first quarter ended June 30, 2026, Replimune reported cash and short-term investments of $195.3 million, down from $268.9 million at March 31, 2026. Research and development expenses were $49.3 million, compared to $57.8 million in the same quarter of the prior year, with the decrease attributed to lower personnel and direct research costs. The company completed a $150 million financing in August 2026, with net proceeds of $141.0 million, to support the commercial launch and confirmatory trial. No revenue was reported in the quarter.

Strategy

Replimune is executing a commercial launch of TUDRIQEV in the U.S. within 60 days of FDA approval, building out commercial infrastructure including a new Chief Commercial Officer. The company is advancing the IGNYTE-3 confirmatory Phase 3 trial, with a primary endpoint of overall survival expected to read out in 2030. It is also enrolling the REVEAL Phase 2/3 trial for RP2 in uveal melanoma, with a Phase 2/3 transition expected in Q1 2027. The strategy includes leveraging the RPx platform for combination with checkpoint inhibitors and expanding its skin cancer franchise.

Risks

• Commercial execution risk — Replimune has no prior commercial experience and must successfully launch TUDRIQEV, build a sales force, and gain market acceptance in a competitive oncology landscape.
• Regulatory risk for confirmatory trial — TUDRIQEV is approved under accelerated approval and may face withdrawal or additional requirements if the confirmatory IGNYTE-3 trial fails to verify clinical benefit.
• Cash runway risk — With$195.3 million at June 30, 2026, the company expects to fund operations for greater than twelve months, but commercial scale-up and trials will require additional capital.
• Clinical development risk — RP2 and RP3 are still in clinical trials with no approvals, subject to enrollment, efficacy, and safety uncertainties that could delay or prevent registration.

Outlook

Management expects to complete the TUDRIQEV commercial launch within 60 days of approval (by early October 2026) and to continue enrollment in the IGNYTE-3 confirmatory trial and the REVEAL trial. The company states that existing cash, including the August 2026 financing proceeds, will fund operations for more than twelve months, covering commercialization scale-up and general corporate purposes. The IGNYTE-3 primary endpoint (overall survival) is expected to read out in 2030.